MedPath

The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction

Not Applicable
Conditions
CRE-induced SBO
Interventions
Registration Number
NCT03642288
Lead Sponsor
Jinling Hospital, China
Brief Summary

Chronic radiation enteropathy (CRE) is a major issue for long-term cancer survivors. The aim of this study was to clarify the diagnostic and therapeutic effect of the Gastrografin (GG) challenge for patients with CRE induced small bowel obstruction SBO.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
112
Inclusion Criteria
  • with a first diagnosis of CRE combined with SBO and ASBO that was determined by clinical history, computed tomography (CT) manifestation, and confirmed by intraoperative and histologic findings.
  • radiation therapy completed at least 6 months before enrolment.
Exclusion Criteria
  • a colostomy or ileostomy;
  • large bowel obstruction;
  • with a known history of either allergy or hypersensitivity to iodinated contrast agents;
  • with signs of strangulation;
  • metastatic disease;
  • obstruction within 4 weeks after a recent operation or serious comorbidity.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CRE-induced SBOGastrografinPatients with CRE-induced SBO received GG challenge.
ASBOGastrografinPatients with adhesive SBO (ASBO) received GG challenge.
Primary Outcome Measures
NameTimeMethod
The rate of successful conservative treatment5 days

The rate of patients who need for operative intervention within 48 hours of randomization.

Secondary Outcome Measures
NameTimeMethod
The time to resolution2 weeks

The time to resolution of ASIO (flatus and bowel motion).

The length of hospital stays2 weeks

The length of hospital stays (in hours, calculated from the hospital admission to resolution of intestinal obstruction).

© Copyright 2025. All Rights Reserved by MedPath